On April 6, 2023 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, reported that its Chief Scientific Officer, Loïc Vincent, Ph.D., reported that it will present data from the Company’s oncogenic driver program targeting KRAS G12D, at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 in Orlando, Florida, taking place April 14th – 19th (Press release, Affini-T Therapeutics, APR 6, 2023, View Source [SID1234629873]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation details are as follows:
Session MS.CL07.01 – Immunotherapy: Sunday, April 16th from 3:52 pm – 4:07 pm ET: Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide